Download PDF
Horm Metab Res 2017; 49(11): 886-891
DOI: 10.1055/s-0043-119089
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial

Neda Roshanravan
1   Nutrition Research Center, Students Research Committee, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
Reza Mahdavi
2   Nutrition Research Center, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
Effat Alizadeh
3   Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Science, Tabriz, Iran
,
Mohammad Asghari Jafarabadi
4   Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
5   Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
,
Mehdi Hedayati
6   Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
,
Abed Ghavami
2   Nutrition Research Center, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
Shahriar Alipour
7   Department of Molecular Medicine, Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
,
Naimeh Mesri Alamdari
8   Student Research Committee, School of Health, Iran University of Medical Science, Tehran, Iran
,
Meisam Barati
2   Nutrition Research Center, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
,
Alireza Ostadrahimi
2   Nutrition Research Center, School of Nutrition, Tabriz University of Medical Science, Tabriz, Iran
› Author Affiliations
Further Information

Publication History

received 05 March 2017

accepted 29 August 2017

Publication Date:
29 September 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Studies on humans with diabetes mellitus showed that the crosstalk between the intestinal microbiota and the host has a key role in controlling the disease. The aim of this study was to evaluate the effects of sodium butyrate and high performance inulin supplementation simultaneously or singly on glycemic status, lipid profile, and glucagon-like peptide 1 level in adults with type 2 diabetes mellitus. Sixty patients were recruited for the study. The participants were randomly allocated, using randomized block procedure, to one of the four treatment groups (A, B, C, or D). Group A received sodium butyrate capsules, group B received inulin supplement powder, group C was exposed to the concomitant use of inulin and sodium butyrate, and group D consumed placebo for 45 consecutive days. Markers of glycemia, lipid profile, and glucagon-like peptide 1 were measured pre- and post-intervention. Dietary supplementation in groups A, B, and C significantly reduced diastolic blood pressure in comparison with the placebo group (p<0.05). Also, intra-group statistical analysis showed that only treatment with sodium butyrate + inulin (group C) significantly reduced fasting blood sugar (p=0.049) and waist to hip ratio (p=0.020). Waist circumference in groups B and C reduced significantly after the intervention (p=0.007 and p=0.011; respectively). The post hoc Tukey tests showed significant increase in glucagon-like peptide 1 concentration in groups A and C in comparison with group D (p<0.05). The results suggest that inulin supplementation may be useful to diabetic patients and these effects could be increased with butyrate supplement.

Key words

high performance inulin - sodium butyrate - glucagon-like peptide 1 - diabetes mellitus - dietary intake - lipid profile

Supplementary Material

    Supplementary Material for this article is available online at http://www.thieme-connect.de/products.
  • Supplementary Material
 

  • References

  • 1 Ruan Y, Sun J, He J, Chen F, Chen R, Chen H. Effect of probiotics on glycemic control: A systematic review and meta-analysis of randomized, controlled trials. PloS one 2015; 10: e0132121
    CrossrefPubMedGoogle Scholar
  • 2 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
    CrossrefPubMedGoogle Scholar
  • 3 Melli L, do Carmo-Rodrigues M, Araújo-Filho H, Solé D, de Morais M. Intestinal microbiota and allergic diseases: A systematic review. Allergol Immunopathol 2016; 44: 177-188
    CrossrefPubMedGoogle Scholar
  • 4 Le Barz M, Anhê FF, Varin TV, Desjardins Y, Levy E, Roy D, Urdaci MC, Marette A. Probiotics as complementary treatment for metabolic disorders. Diabetes metab J 2015; 39: 291-303
    CrossrefPubMedGoogle Scholar
  • 5 Ericsson AC, Franklin CL. Manipulating the gut microbiota: Methods and challenges. ILAR J 2015; 56: 205-217
    CrossrefPubMedGoogle Scholar
  • 6 Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-514
    CrossrefPubMedGoogle Scholar
  • 7 Pineiro M, Asp N-G, Reid G, Macfarlane S, Morelli L, Brunser O, Tuohy K. FAO Technical meeting on prebiotics. J Clin Gastroenterol 2008; 42: S156-S159
    CrossrefPubMedGoogle Scholar
  • 8 de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008; 111: 1-66
    PubMedGoogle Scholar
  • 9 Kolida S, Meyer D, Gibson G. A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr 2007; 61: 1189-1195
    CrossrefPubMedGoogle Scholar
  • 10 Flamm G, Glinsmann W, Kritchevsky D, Prosky L, Roberfroid M. Inulin and oligofructose as dietary fiber: A review of the evidence. Crit Rev Food Sci Nutr 2001; 41: 353-362
    CrossrefPubMedGoogle Scholar
  • 11 Kolida S, Gibson GR. Prebiotic capacity of inulin-type fructans. J Nutr 2007; 137: 2503S-2506S
    CrossrefPubMedGoogle Scholar
  • 12 Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—approaching a definition. Am J Clin Nutr 2001; 73: 361s-364s
    CrossrefPubMedGoogle Scholar
  • 13 Cummings J, Pomare E, Branch W, Naylor C, Macfarlane G. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-1227
    CrossrefPubMedGoogle Scholar
  • 14 McIntyre A, Gibson P, Young G. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 1993; 34: 386-391
    CrossrefPubMedGoogle Scholar
  • 15 Singh B, Halestrap AP, Paraskeva C. Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Carcinogenesis 1997; 18: 1265-1270
    CrossrefPubMedGoogle Scholar
  • 16 Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 320: 23-28
    CrossrefPubMedGoogle Scholar
  • 17 Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509-1517
    CrossrefPubMedGoogle Scholar
  • 18 Ahmad M, Krishnan S, Ramakrishna B, Mathan M, Pulimood A, Murthy S. Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut 2000; 46: 493-499
    CrossrefPubMedGoogle Scholar
  • 19 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439
    CrossrefPubMedGoogle Scholar
  • 20 Sa’ad H, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 2010; 1801: 1175-1183
    CrossrefPubMedGoogle Scholar
  • 21 Hur KY, Lee M-S. Gut microbiota and metabolic disorders. Diabetes Metab J 2015; 39: 198-203
    CrossrefPubMedGoogle Scholar
  • 22 Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-S69
    CrossrefPubMedGoogle Scholar
  • 23 Dehghan P, Gargari BP, Asgharijafarabadi M. Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: A randomized, placebo-controlled clinical trial. Health Promot Perspect 2013; 3: 55-63
    PubMedGoogle Scholar
  • 24 Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen J-P. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013; 62: 1112-1121
    CrossrefPubMedGoogle Scholar
  • 25 Guess ND, Dornhorst A, Oliver N, Bell JD, Thomas EL, Frost GS. A randomized controlled trial: The effect of inulin on weight management and ectopic fat in subjects with prediabetes. Nutr Metab 2015; 12: 36-46
    CrossrefPubMedGoogle Scholar
  • 26 Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009; 89: 1751-1759
    CrossrefPubMedGoogle Scholar
  • 27 Dehghan P, Gargari BP, Jafar-Abadi MA. Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: A randomized controlled clinical trial. Nutrition 2014; 30: 418-423
    CrossrefPubMedGoogle Scholar
  • 28 Fernandes R, do Rosario VA, Mocellin MC, Kuntz MG, Trindade EB. Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review. Clin Nutr 2016; 113: 1-10
    PubMedGoogle Scholar
  • 29 Morel FB, Dai Q, Ni J, Thomas D, Parnet P, Fança-Berthon P. α-Galacto-oligosaccharides dose-dependently reduce appetite and decrease inflammation in overweight adults. J Nutr 2015; 145: 2052-2059
    CrossrefPubMedGoogle Scholar
  • 30 Säemann MD, Böhmig GA, Österreicher CH, Burtscher H, Parolini O, Diakos C, Stöckl J, Hörl WH, Zlabinger GJ. Anti-inflammatory effects of sodium butyrate on human monocytes: Potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 2000; 14: 2380-2382
    CrossrefPubMedGoogle Scholar
  • 31 Cordel S, Dupas B, Douillard JY, Meflah K. Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance. Int J Cancer 1998; 78: 735-739
    CrossrefPubMedGoogle Scholar
  • 32 Krokowicz L, Stojcev Z, Kaczmarek BF, Kociemba W, Kaczmarek E, Walkowiak J, Krokowicz P, Drews M, Banasiewicz T. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study. Int J Colorectal Dis 2014; 29: 387-393
    CrossrefPubMedGoogle Scholar
  • 33 Canani RB, Terrin G, Cirillo P, Castaldo G, Salvatore F, Cardillo G, Coruzzo A, Troncone R. Butyrate as an effective treatment of congenital chloride diarrhea. Gastroenterology 2004; 127: 630-634
    CrossrefPubMedGoogle Scholar
  • 34 Wolever T, Brighenti F, Royall D, Jenkins AL, Jenkins DJ. Effect of rectal infusion of short chain fatty acids in human subjects. Am J Gastroenterol 1989; 84: 1027-1033
    PubMedGoogle Scholar
  • 35 Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110: 9066-9071
    CrossrefPubMedGoogle Scholar
  • 36 Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P, de Vos WM. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011; 60: 2775-2786
    CrossrefPubMedGoogle Scholar
  • 37 Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013; 4: 1829-1841
    CrossrefPubMedGoogle Scholar
  • 38 Causey JL, Feirtag JM, Gallaher DD. Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal environment in hypercholesterolemic men. Nutr Res 2000; 20: 191-201
    CrossrefPubMedGoogle Scholar